Open Access Open Access  Restricted Access Subscription Access

A Review on Study Drug Delivery System via Transdermal Application

Mansi B. Patil, Mahima R. Patil, Hitendra S. Chaudhari, Sunil P. Pawar, Roshan M Chaudhari, Rahul B. Lovhare, Azam Z. Shaikh

Abstract


To create fundamental outcomes, transdermal medication conveyance frameworks (TDDS), likewise alluded to as "patches," are dose structures expected to disseminate a remedially dynamic amount of prescription into a patient's skin. Drugs are applied topically utilizing transdermal medication conveyance frameworks. These are variously sized pharmacological formulations containing one or more active ingredients. By applying the active ingredient to the skin after it has crossed the barriers, they are intended to be applied topically to the undamaged skin, preventing first pass metabolism. Currently, 74% of prescription drugs are taken orally, where they may not have the desired impact. Systems for administering medications transdermally were created to boost effectiveness. With TDDS, the drug easily penetrates the skin and reaches the desired location. transdermal administration of medication devices were developed to address the problems associated with the delivery of oral medications. These frameworks have been used as dependable and secure medication conveyance techniques beginning around 1981.

A transdermal fix is a cured cement fix that is put on the skin to convey a particular portion of medicine through the skin and into fundamental course. Often, this promotes healing to an injured area of the body. Compared to other methods of medication delivery, such as oral, topical, intravenous, intramuscular, etc., a transdermal drug delivery route has the advantage of allowing for controlled medication release into the patient through the patch. This is commonly accomplished by either a permeable film covering a supply of drug or by body heat dissolving flimsy layers of prescription implanted in the cement.


Full Text:

PDF

References


Thombre, A.G. and Cardinal, J.R. Biopolymers for controlled drug delivery. In: Swarbrick, J. and Boylon, J.C. Eds, Encyclopedia of Pharmaceutical Technology. Vol.2, Marcel Dekker Inc.; New York; 1990. pp 61.

Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems. Pharm se Technol. 2002; 26(5):62–81.

Divya A, Rao MK, Gnanprakash K, Sowjanya A, Vidyasagar N, Gobinath M. A review on current scenario of transdermal drug delivery system. Int J Res Pharm Sci. 2012; 3(4):494–502.

Prausnitz, M. R., Mitragotri, S., and Langer, R. (2004). Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov. 3, 115–124. Doi:10.1038/nrd1304.

Ghosh, T.K. and Banga, A.K. Methods of enhancement of transdermal drug delivery: Part I. Physical and Biochemical Approaches. Pharmaceutical Technology.1993; 75-78.

Chein YW. Transdermal Controlled Systemic Medication. New York and Basel: Marcel

Dekker Inc; 1987.

Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a review.

Pharm Innov. 2012; 1: 66–75.

Bowen, A.J., John, V.A., Ramirez, M.E. and Good, W.R. Bioavailability of oestradiol from the Alora (0.1 mg/day) oestradiol matrix transdermal delivery system compared with Estraderm (0.1mg/day), J. Obstet and Gynecol. 1998; 18(6): 575-580.

Dalby, R. Transdermal drug delivery, School of pharmacy, Baltimore.

Sharma, S.N. and Popii, H. Transdermal drug delivery system, The Eastern Pharmacist. 1990;41-42.


Refbacks

  • There are currently no refbacks.